Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Accentia, Inc.
Controlling interest of cancer vaccine company acquired
July 30th, 2003
Accentia, Inc., a Hopkins Capital Group portfolio company, and Biovest International jointly announced Accentia's acquisition of an 81% equity interest in Biovest for a purchase price of $20 million dollars in cash and notes. Accentia is a privately held specialty pharmaceutical and services company. The closing of this transaction provides additional resources for Biovest, including access to additional working capital infrastructure and biopharmaceutical relationships. Biovest is conducting a pivotal phase III trial of its personalized therapeutic cancer vaccine for non-Hodgkin lymphoma in cooperation with the National Cancer Institute...
Source: Biotech Week (2003-07-30)
|
